These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10134128)

  • 21. An analysis of potential and real cost savings by the addition of ranitidine to total parenteral nutrition solutions.
    Pearson VE; King LM
    Hosp Pharm; 1992 Jul; 27(7):610, 613-4. PubMed ID: 10119189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic surveillance: the results of a clinical pharmacy intervention program.
    Capers CC; Bess DT; Branam AC; Falbe WJ; Mrochek SA; Haymond JD; Stahl AA
    Hosp Pharm; 1993 Mar; 28(3):206-10, 212. PubMed ID: 10124947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacoeconomic analysis of IV H2-receptor antagonist use in 40 hospitals.
    Segal R; Oh T; Ben-Joseph R; Russell WL
    Hosp Formul; 1994 May; 29(5):379-82, 388-91. PubMed ID: 10136601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving parenteral nutrition cost savings through prescribing guidelines and formulary restrictions.
    Maswoswe JJ; Newcomer DR; Quandt CM
    Am J Hosp Pharm; 1987 Jun; 44(6):1376-81. PubMed ID: 3113237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A practical approach to achieving a $950,000 cost savings from a joint anesthesia-pharmacy program.
    Durfee DD
    Hosp Pharm; 1995 Nov; 30(11):957-8, 961-3. PubMed ID: 10152916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How pharmaceutical controls worked in one Ontario hospital.
    McLean WM; Tierney MG
    Can J Hosp Pharm; 1994 Aug; 47(4):176-9. PubMed ID: 10136951
    [No Abstract]   [Full Text] [Related]  

  • 28. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost savings achieved through cephalosporin use review and restriction.
    Dzierba SH; Reilly RT; Caselnova DA
    Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of benchmarking techniques to justify the evolution of antibiotic management programs in healthcare systems.
    Schentag JJ; Paladino JA; Birmingham MC; Zimmer G; Carr JR; Hanson SC
    J Pharm Technol; 1995; 11(5):203-10. PubMed ID: 10151512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
    Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two methods for allocating pharmacy cost per patient case.
    Pink GH; Bolley HB; Cockerill RW
    Am J Hosp Pharm; 1994 May; 51(10):1331-4. PubMed ID: 8085571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?
    Nathwani D
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii37-44. PubMed ID: 12730141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
    Kane MP; Briceland LL; Garris RE; Favreau BN
    Am J Hosp Pharm; 1990 Sep; 47(9):2007-10. PubMed ID: 1977317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. G-CSF (Granulocyte Colony-Stimulating Factor): follow-up and use in a French University hospital.
    Furet I; Closson V; Madelaine I; Faure P
    Can J Hosp Pharm; 1995 Apr; 48(2):90-7. PubMed ID: 10142843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost savings from dose rounding of biologic anticancer agents in adults.
    Winger BJ; Clements EA; DeYoung JL; O'Rourke TJ; Claypool DL; Vachon S; VanDyke TH; Zimmer-Young J; Kintzel PE
    J Oncol Pharm Pract; 2011 Sep; 17(3):246-51. PubMed ID: 20332175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economics of providing antineoplastic drugs in a manufacturer-mixed bulk package.
    Kleinberg ML; Duafala ME
    Am J Hosp Pharm; 1988 Jan; 45(1):109-15. PubMed ID: 3348222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the Hospital Pharmacy Initiative for promoting prudent use of antibiotics in hospitals in England.
    Wickens HJ; Jacklin A
    J Antimicrob Chemother; 2006 Dec; 58(6):1230-7. PubMed ID: 17030518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective drug utilization evaluation of vancomycin usage in paediatric patients.
    Hing WC; Bek SJ; Lin RT; Li SC
    J Clin Pharm Ther; 2004 Aug; 29(4):359-65. PubMed ID: 15271103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.